Gagnon, Marie-France
Tian, Shulan
Geyer, Susan
Sharma, Neeraj http://orcid.org/0000-0002-8229-3083
Vachon, Celine M. http://orcid.org/0000-0002-1962-9322
Kusne, Yael
Bergsagel, P. Leif http://orcid.org/0000-0003-1523-7388
Stewart, A. Keith
Rajkumar, S. Vincent http://orcid.org/0000-0002-5862-1833
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
Baughn, Linda B. http://orcid.org/0000-0001-5229-4897
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA186781)
Article History
Received: 11 May 2022
Revised: 4 July 2022
Accepted: 8 July 2022
First Online: 26 July 2022
Competing interests
: SK served as a consultant for Celgene, Takeda, Amgen, Janssen, and Bristol Myers Squibb and received research funding from Celgene, Takeda, Novartis, Amgen, AbbVie, Janssen, and Bristol Myers Squibb. SA receives honoraria from Celgene and Takeda as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune, and Phosplatin. AKS was a consultant for Bristol Myers Squibb, Celgene, Amgen, Janssen, Takeda, and Roche. The remaining authors declare no competing financial interests related to this work.